Skip to main content
Evidence Snapshot

Alpha-synuclein

CHEMBL6152 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T15:13:16Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL6152
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Alpha-synuclein as ChEMBL target CHEMBL6152, mapped to UniProt P37840. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Alpha-synuclein
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL6152
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P37840
Alpha-synuclein
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Alpha-synuclein matters

As of 2026-09-13

Alpha-synuclein is reviewed as Alpha-synuclein (UniProt P37840); Alpha-synuclein shows clinical signal disease relevance led by Parkinson disease.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 18 approved drugs, 10960 compounds, and 410 assays, with lead potency reaching pChEMBL 9.3.

Disease context
Parkinson disease

Alpha-synuclein shows clinical signal disease relevance led by Parkinson disease. 2 linked drugs keep the rationale reviewable. Linked drugs include CINPANEMAB, PRASINEZUMAB.

Start review with Parkinson disease because it currently carries clinical signal support. Linked drugs include CINPANEMAB, PRASINEZUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 2 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 18 approved drugs, 10960 compounds, and 410 assays for this target. The dominant activity type is IC50. CHEMBL5896450 is the current potency anchor at pChEMBL 9.3.

Use CHEMBL5896450 as the tractability anchor when discussing potency (pChEMBL 9.3).

Activity source · ChEMBL 36 via Core Engine
18 approved pChEMBL 9.3
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Alpha-synuclein matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P37840, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Parkinson disease is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

10960
Total Compounds
410
Total Assays
18
Approved Drugs
IC50: 192.0, KI: 130.0, EC50: 90.0, KD: 141.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5896450
 9.3 Kd —
No preferred name
CHEMBL5771524
 9.3 Kd —
No preferred name
CHEMBL5790440
 9.1 Kd —
No preferred name
CHEMBL5843241
 9.1 Kd —
No preferred name
CHEMBL5843281
 9.0 Kd —

Approved Drugs

Structure Compound First Approval
FLORBETAPIR
CHEMBL1908919
 2012
SELEGILINE
CHEMBL972
 1989
CEFTRIAXONE
CHEMBL161
 1984
RETINOL
CHEMBL986
 1982
DOPAMINE
CHEMBL59
 1974
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T15:13:16Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL6152